세계의 바이오마커 검사 서비스 시장 : 서비스별, 기술별, 질환 영역별, 용도별, 최종 사용자별 예측(2025-2030년)

The Biomarker Testing Services Market was valued at USD 964.90 million in 2023, expected to reach USD 1,031.96 million in 2024, and is projected to grow at a CAGR of 7.34%, to USD 1,585.04 million by 2030.

Biomarker testing services encompass diagnostic processes that utilize biomarkers to detect, evaluate, and monitor health conditions, particularly in oncology, neurology, cardiology, and infectious diseases. This testing is essential for precision medicine, wherein treatments can be tailored to the individual's genetic profile, often leading to better outcomes. The application of biomarker testing spans early disease diagnosis, therapeutic guidance, prognosis, and monitoring treatment response. Within the market, the primary end-users are hospitals, diagnostic laboratories, research organizations, and pharmaceutical companies. Key growth factors include the rise in chronic diseases, advancements in genomics and proteomics, and an increased focus on personalized medicine. Technological advancements, particularly in next-generation sequencing and digitalized diagnostics, present opportunities to expand and refine biomarker applications. Companies can capitalize by investing in partnerships and collaborations with genomic research entities to develop co-branded diagnostic solutions.

However, the market faces limitations such as high costs associated with biomarker discovery and validation, regulatory challenges around multi-analyte assays, and data management issues. Challenges also arise in standardization and the integration of diverse biomarker types for comprehensive analysis. Innovations should focus on reducing costs via automated and integrated platforms, enhancing data integration strategies, and developing robust, scalable validation methodologies. Another promising area is the integration of AI to streamline biomarker discovery and data interpretation processes. The market is highly dynamic, characterized by rapid technological advancements and competitive differentiation through value-added services. Success in this field requires a strategic approach towards fostering collaborations, investing in advanced technologies, and complying with regulatory environments. Staying updated with industry trends and prioritizing customer-centric innovations will be crucial to capturing market opportunities and driving company growth in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biomarker Testing Services Market

The Biomarker Testing Services Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing cancer drug development and need for high-performing biomarkers
  • Government initiatives and investments for biomarker research
  • Improved availability of financial coverage for biomarker testing
• Market Restraints
  • Time-consuming and expensive process of biomarker testing
• Market Opportunities
  • Advancements in biomarker testing tools & equipment with AI & ML
  • Emerging CDMOs offering biomarker testing and analysis services
• Market Challenges
  • Barriers in testing due to lack of sample collection and authenticity

Porter's Five Forces: A Strategic Tool for Navigating the Biomarker Testing Services Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biomarker Testing Services Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biomarker Testing Services Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biomarker Testing Services Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biomarker Testing Services Market

A detailed market share analysis in the Biomarker Testing Services Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biomarker Testing Services Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biomarker Testing Services Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biomarker Testing Services Market

A strategic analysis of the Biomarker Testing Services Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biomarker Testing Services Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC by Danaher Corporation, Agilent Technologies, Inc., Avid Bioservices, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, BiomarkerBay B. V., Bristol Myers Squibb, Eurofins Scientific SE, F. Hoffmann-La Roche AG, Icon PLC, Intertek Group PLC, IQVIA, JSR Life Sciences, LLC, KCAS Group, Laboratory Corporation of America Holdings, LGC Group, Merck KGaA, Myriad Genetics, Inc., NeoGenomics Laboratories, Parexel International Corporation, PerkinElmer Inc., Randox Laboratories, SGS S.A., Shuwen Biotech Co., Ltd., Syneos Health, Thermo Fisher Scientific, Inc., and WuXi Biologics Inc..

Market Segmentation & Coverage

This research report categorizes the Biomarker Testing Services Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Services, market is studied across Biomarker Assay Development & Validation and Flow Cytometry.
• Based on Techonology, market is studied across Enzyme-Linked Immunosorbent Assay, Mass Spectrometry, Next-Generation Sequencing, and Polymerase Chain Reaction.
• Based on Disease Area, market is studied across Autoimmune Diseases, Cancer, Cardiovascular Diseases, and Neurological Disorders.
• Based on Application, market is studied across Drug Mechanism of Action, Pharmacodynamic, Predictive Clinical Studies, and Prognostic.
• Based on End-User, market is studied across Contract Research Oraganizations, Pharmaceutical & biotechnology companies, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing cancer drug development and need for high-performing biomarkers
    • 5.1.1.2. Government initiatives and investments for biomarker research
    • 5.1.1.3. Improved availability of financial coverage for biomarker testing
  • 5.1.2. Restraints
    • 5.1.2.1. Time-consuming and expensive process of biomarker testing
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in biomarker testing tools & equipment with AI & ML
    • 5.1.3.2. Emerging CDMOs offering biomarker testing and analysis services
  • 5.1.4. Challenges
    • 5.1.4.1. Barriers in testing due to lack of sample collection and authenticity
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Ongoing advancements to improve the versatility, speed, and amplification capabilities of polymerase chain reaction technology
  • 5.2.2. End-User: Emerging utilization of biomarker testing services by pharmaceutical & biotechnology companies for therapeutic interventions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biomarker Testing Services Market, by Services

• 6.1. Introduction
• 6.2. Biomarker Assay Development & Validation
• 6.3. Flow Cytometry

7. Biomarker Testing Services Market, by Techonology

• 7.1. Introduction
• 7.2. Enzyme-Linked Immunosorbent Assay
• 7.3. Mass Spectrometry
• 7.4. Next-Generation Sequencing
• 7.5. Polymerase Chain Reaction

8. Biomarker Testing Services Market, by Disease Area

• 8.1. Introduction
• 8.2. Autoimmune Diseases
• 8.3. Cancer
• 8.4. Cardiovascular Diseases
• 8.5. Neurological Disorders

9. Biomarker Testing Services Market, by Application

• 9.1. Introduction
• 9.2. Drug Mechanism of Action
• 9.3. Pharmacodynamic
• 9.4. Predictive Clinical Studies
• 9.5. Prognostic

10. Biomarker Testing Services Market, by End-User

• 10.1. Introduction
• 10.2. Contract Research Oraganizations
• 10.3. Pharmaceutical & biotechnology companies
• 10.4. Research Institutes

11. Americas Biomarker Testing Services Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Biomarker Testing Services Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Biomarker Testing Services Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Mayo Clinic Laboratories and Progentec Collaborate To Bring Advanced Biomarker Testing Services To Patients With Autoimmune Diseases
  • 14.3.2. Novel Prostate Cancer Biomarker Test Launches on US Market
  • 14.3.3. Quanterix Launches LucentAD Biomarker Blood Test To Aid Physician Diagnosis of Alzheimer's Disease In Patients
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abcam PLC by Danaher Corporation
• 2. Agilent Technologies, Inc.
• 3. Avid Bioservices, Inc.
• 4. Bio-Rad Laboratories, Inc.
• 5. BioAgilytix Labs
• 6. BiomarkerBay B. V.
• 7. Bristol Myers Squibb
• 8. Eurofins Scientific SE
• 9. F. Hoffmann-La Roche AG
• 10. Icon PLC
• 11. Intertek Group PLC
• 12. IQVIA
• 13. JSR Life Sciences, LLC
• 14. KCAS Group
• 15. Laboratory Corporation of America Holdings
• 16. LGC Group
• 17. Merck KGaA
• 18. Myriad Genetics, Inc.
• 19. NeoGenomics Laboratories
• 20. Parexel International Corporation
• 21. PerkinElmer Inc.
• 22. Randox Laboratories
• 23. SGS S.A.
• 24. Shuwen Biotech Co., Ltd.
• 25. Syneos Health
• 26. Thermo Fisher Scientific, Inc.
• 27. WuXi Biologics Inc.